

Reference:	FOI.17346.25
Subject:	Spinal Muscular Atrophy
Date of Request:	15 May 2025

Requested:

1. How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your trust?
2. How many patients have been treated in the last 4 months (January to April 2025) with the following products:
 - Evrysdi (Risdiplam)
 - Spinraza (Nusinersen)
 - Zolgensma (Onasemnogene)

Response:

1. Hywel Dda University Health Board (UHB) confirms that eight (8) inpatients have been diagnosed with Spinal Muscular Atrophy, as is recorded on the Welsh Patient Administration system (WPAS).
2. The UHB confirms that it has not prescribed any of the listed medicines during the requested periods covering 1 January to 30 April 2025. These medications are Advanced Therapy Medicinal Products (ATMPs) or gene therapies for rare diseases, and they are prescribed and administered in specialist centres, commissioned through NHS Wales Joint Commissioning Committee (NWJCC).